BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
LATEST POSTS
- 1
Bring tissues and skip the mascara: The movie that's making theater-goers sob uncontrollaby - 2Some gifted dogs can learn new toy names by eavesdropping on owners
- 3The risk of falling space junk hitting airplanes is on the rise, experts warn
- 4The 15 Best Business visionaries Under 40
- 5Disney's latest short film 'Versa' tackles a difficult subject: Pregnancy loss. It's resonating with viewers.
- Pick Your Favored method of transportation
- Journeys That could only be described as epic: Delightful Voyage Lines All over the Planet
- 6 Tire Brands Reasonable for Seniors
- Israel reports second missile fire from Yemen since start of Iran war
- How to sound like an astronaut as you follow the first human moon mission in more than half a century
- Plans for ‘stop anywhere’ night buses recommended by government for women’s safety
- Luigi Mangione‘s lawyers say Bondi’s death penalty decision was tainted by conflict of interest
- South Carolina measles outbreak grows by nearly 100, spreads to North Carolina and Ohio
- Kobe Bryant called this WNBA star the 'Gold Mamba.' She turned his advice to her into a tattoo.
